IMM
Asset Logo

Immutep Limited

๐Ÿ‡ฆ๐Ÿ‡บ ASX

๐Ÿงฌ BIOTECHNOLOGY

๐Ÿ•Š๏ธ SOCIALLY AWARE

Compare
Add to watchlist
๐Ÿ‘‘ Overview

๐Ÿ“ˆ Performance

๐Ÿ’ต Cost

๐Ÿƒ Esg

๐Ÿค“ Advanced

๐Ÿ‘จโ€๐Ÿ‘ฉโ€๐Ÿ‘งโ€๐Ÿ‘ฆ Community

๐Ÿ“ˆ

+ 180.00%
Annual Growth

5 years average annual growth

๐Ÿ’ต

$ 500
Minimum Order

Due to regulatory requirements

๐ŸŒ

8
Pearlers Invested

Since January 2020

๐Ÿ‘‘ Overview

Key information
๐Ÿ”Ž Fund Overview

Immutep Ltd. is a clinical stage biotechnology company, which engages in the development of LAG-3 related immunotherapeutic products for cancer and autoimmune diseases. The company is headquartered in Sydney, New South Wales. The firm is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3โ€™s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

๐Ÿ“ˆ Performance

Price History

-30.00%

1M

1Y

10Y

Graph

Table

Unsure how much or often to invest?
๐Ÿ—“๏ธ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out โ†’
๐Ÿ’ต Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out โ†’
โฑ๏ธ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out โ†’

๐Ÿ’ต Costs

๐Ÿ’ต

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

๐Ÿ’ผ

N/A
Management Fee

Included in unit price, not charged by Pearler

๐Ÿ’ธ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
๐Ÿ’ธ Net fee calculator

๐Ÿƒ Environmental, Social and Governance scores โ„น๏ธ

๐ŸŒณ

Environmental Score
55

A measure of an organisations or investment's impact on the natural environment, including factors such as carbon emissions, resource usage, and pollution

๐Ÿ•Š๏ธ

Social Score
99

An assessment of an organisations management practices, board structure, transparency, and accountability, reflecting its commitment to ethical behavior and responsible decision-making.

โš–๏ธ

Governance Score
35

An evaluation of an organisations impact on society, focusing on factors such as employee welfare, diversity and inclusion, community engagement, and product safety and quality.

๐Ÿค“ Advanced information

Technical Info

๐Ÿ’ฐ Price*

$0.28

*Price may be up to 24 hours old

๐Ÿ‘ฉโ€๐Ÿ‘ฉโ€๐Ÿ‘ฆ Community Insights

How our community is investing

๐ŸŒ Pearlers invested in IMM

8

๐Ÿ“Š Total Capital Earnings

$806.43

๐Ÿ”ƒ Average investment frequency

17 weeks

๐Ÿ’ต Average investment amount

$3,908

โฐ Last time a customer invested in IMM

77 days
IMM investor breakdown
๐Ÿ’ต Income of investors

More than 200k

10%

150k - 200k

10%

100k - 150k

20%

50k - 100k

20%

Less than 50k

30%
๐Ÿ‘ถ Age of investors

18 - 25

26 - 34

35 - 90

88%
๐Ÿ™‹ Legal gender of investors

Female

38%

Male

63%

Pearlers who invest in IMM also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

3.94%

๐Ÿ“Š Share price

$101.26 AUD

๐Ÿ‡ฆ๐Ÿ‡บ AUSTRALIA

๐Ÿ’ธ FINANCIALS

๐Ÿงฑ MATERIALS

โ›ณ๏ธ DIVERSIFIED

Find Out More

Imugene Ltd. is a biopharmaceutical company, which engages in the research, development, and commercialisation of health technologies against cancer. The company is headquartered in Sydney, New South Wales. The company is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the bodyโ€™s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.

๐Ÿ™Œ Performance (5Yr p.a)

18.26%

๐Ÿ“Š Share price

$0.04 AUD

๐Ÿงฌ BIOTECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH

VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

3.74%

๐Ÿ“Š Share price

$66.59 AUD

โ›ณ๏ธ DIVERSIFIED

๐ŸŒ GLOBAL

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

๐Ÿ™Œ Performance (5Yr p.a)

12.93%

๐Ÿ“Š Share price

$129.83 AUD

๐Ÿค– TECHNOLOGY

๐Ÿ“ˆ HIGH PRICE GROWTH

๐ŸŒ GLOBAL

โ›ณ๏ธ DIVERSIFIED

ACDC.AX was created on 2018-08-30 by Global X. The fund's investment portfolio concentrates primarily on theme equity. The ETF currently has 493.8m in AUM and 35 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the Solactive Battery ValueChain Index (the Index).

๐Ÿ™Œ Performance (5Yr p.a)

13.80%

๐Ÿ“Š Share price

$83.40 AUD

๐Ÿ“ˆ HIGH PRICE GROWTH

๐Ÿค– TECHNOLOGY

๐Ÿ‡ฆ๐Ÿ‡บ EX AUSTRALIA

๐Ÿญ INDUSTRIALS

Want more shares? Try these...

IMPQ.AX was created on 2021-09-29 by Perennial. The fund's investment portfolio concentrates primarily on total market equity. The objective of the Fund is to deliver long-term capital growth predominately through investments in Australian and New Zealand listed smaller and mid-cap companies that are Better Future Investments.

๐Ÿ™Œ Performance (5Yr p.a)

2.63%

๐Ÿ“Š Share price

$4.91 AUD

๐Ÿ’ธ FINANCIALS

Imricor Medical Systems, Inc. is a medical device company, which engages in the design, manufacture, and distribution of magnetic resonance imaging (MRI) compatible products for cardiac catheter ablation procedures. The company is headquartered in Burnsville, Minnesota. The company went IPO on 2019-08-30. The firm is engaged in designing, manufacturing, and selling MRI-compatible products for cardiac catheter ablation procedures to treat arrhythmias. Its products include Vision-mitral regurgitation (MR) Ablation Catheter, Advantage-MR electrophysiology (EP) Recorder/Stimulator and Vision-MR Dispersive Electrode. The Vision-MR Ablation Catheter is designed to work under real-time MRI guidance. Advantage-MR EP Recorder/Stimulator System provides technology that allows physicians to utilize both the EP recording system and a cardiac stimulator while ablating within the iCMR environment. The firm sells its products to hospitals and clinics for use in iCMR labs, in which ablation procedures using the Vision-MR Ablation Catheter can be performed.

๐Ÿ™Œ Performance (5Yr p.a)

-6.70%

๐Ÿ“Š Share price

$0.74 AUD

๐Ÿฉบ HEALTH CARE

Infinity Mining Ltd. engages in the exploration and development of gold, copper, base metals and lithium mineral properties. These tenements are located in highly prospective Lithium, Nickel, Copper and Gold terranes. The firm's is focused on substantial East Pilbara lithium assets. The Pilbara project tenements comprise an extensive portfolio of Lithium, Gold, Nickel, Copper and Zinc exploration tenements located in the Pilbara region of northwest Western Australia, including the Tambourah South, Tambourah North, Strelley Gorge, Hillside and Panorama Projects. The Tambourah South Project is located 80 kilometers (km) southwest of Marble Bar and 155 km south of Port Headland. The Panorama Project encompasses three tenements and is prospective for a range of target types. The Central Goldfields region is host to deposits of gold, base metals and nickel hosted within greenstone belts and granite intrusives.

๐Ÿ“Š Share price

$0.02 AUD

โ›๏ธ MINING

IMLC.AX was created on 2023-08-01 by IML. The fund's investment portfolio concentrates primarily on total market equity. The Fund aims to outperform the S&P/ASX 300 Accumulation Index (after fees and expenses and before taxes) on a rolling four-year basis.

๐Ÿ“Š Share price

$3.99 AUD
Compare
Add to watchlist